phate-glucuronic acid. Bilirubin UGT, one member of this family, is essential for the excretion of bilirubin, a toxic metabolite derived from hemoproteins, into the bile (I).
In 1952, Crigler and Najjar (2) described a syndrome, CN type I, that featured severe chronic nonhemolytic unconjugated hyperbilirubinemia. In such cases, no bilirubin UGT activity can be detected in hepatic cells (3, 4) . The patients with CN type I may succumb to kernicterus during the neonatal period (5) unless treated with phototherapy, plasmapheresis, liver transplantation, or some combination. The syndrome is inherited as an autosomal recessive trait and is clinically manifested only in its homozygous state (6) . Usually, bilirubin levels reach 342-855 rmol/L in the serum. Traces of unconjugated and monoconjugated bilirubins have been detected in the bile of some patients (6) .
CN type 11, which is also characterized by marked unconjugated hyperbilirubinemia, was identified by Arias (7) in 1962. Compared with the course of CN type I, the clinical course in CN type I1 is almost always benign (e.g. total bilirubin level in the serum, 137-342 rmol/L) because hepatic bilirubin UGT activity, although at a reduced level, can be detected.
A major distinction between types I and I1 of this disorder is as follows: in patients with CN type 11, administration of phenobarbital results in enhanced excretion of the glucuronide conjugates of bilirubin in the bile (8), as well as abrupt decreases in serum bilirubin levels (3, 8) , whereas no effect on the concentration of bilirubin in the serum is observed on administration of phenobarbital to patients with CN type I (3).
Nowadays, it is possible to analyze the genetic background of CN types I and I1 in molecular level. Ritter et al. (9) reported the isolation and characterization of cDNA for two human liver bilirubin UGT, UGT I A [UGT 1 * I ( 1 O)] and UGT 1 D [UGT I *4
( 1 O)]. The UGT 1A and UGT 1 D genes belong to the UGT I locus ( 1 I), which is a complex of six overlapping transcriptional units and encodes at least six isoforrns of UGT, including phenol UGT (1 1, 12). The mRNA for two bilirubin UGT, as well as those for the other four UGT, have a common 3' terminal region composed of four exons (exons 2, 3,4, and 5), whereas the 5' half of each is derived from exons I that are specific to each isoform (1 1, 12). These findings suggest that in CN type I a genetic defect exists in both UGT 1 A and UGT 1 D in the common exons of the two genes, whereas in CN type I1 a defect exists in either of the UGTlA and UGTID, that is to say, in the exon I of the UGTlA gene or in that of UGTI D gene or in a partial defect in exons 2, 3, 4, or 5 (13) . Indeed, five cases of genetic mutation in the common exons of the UGTl A and UGTl D genes have been found in patients with CN type I (12, 14-16).
We have analyzed the genetic background of a patient who was diagnosed as having CN type I on the basis of cardinal symptoms. Here we report the new type of mutation form in this patient, namely, a nonsense mutation in exon 1 of the UGT 1 A gene.
MATERIALS AND METHODS
Human subjects. Blood samples were collected from a I-y-old male CN type I patient, his parents, elder brother, and two unrelated normal males for DNA analysis. The patient was born after a 40-wk gestation, weighing 2752 g, to clinically normal parents, whose total bilirubin levels in the serum were 2 1 and 17 pmol/L. According to the census register, the parents of the patient were nonconsanguineous. Jaundice appeared at 4 d of age, and the total bilirubin level in the serum was 359 pmol/L. At 20 d of age, total and direct bilirubin levels were 530 pmol/L and 39 pmol/L, respectively, so this patient received treatment in the hospital. The mother was 0 positive, and the child was A positive. Results for direct and indirect Coombs' tests were negative for both. Serum bilirubin levels were not lowered by administration of phenobarbital (10 mg/kg/d) for 20 d from d 29 to 48 after birth, and no more than trace quantities of bilirubin conjugates were detectable by HPLC (17) in the blood and duodenal bile of the patient. Serum bilirubin levels in the father and mother of the patient were 2 1 and 17 pmol/L, respectively.
Preparation of genomic DNA from lymphocytes. Genomic DNA was isolated from white blood cells by the method of Poncz ef al. (18) . The DNA, dissolved in 10 mM Tris-HC1 buffer (pH 7.5) that contained 1 mM EDTA, was used as a template for PCR.
Amplification by PCR from genomic DNA. Four pairs of oligonucleotide primers for PCR (Table 1) and 16 primers for sequencing (Table 2) were designed by modifying the primers described by Bosma et al. (12) . The unique exons 1 of the UGT 1 A and UGT 1 D genes and exon 5 were amplified separately by use of each pair of specific primers. Exons 2,3, and 4 and the intervening introns were amplified simultaneously with the u p stream primer of exon 2 and the downstream primer of exon 4 as described elsewhere ( 12) .
PCR was performed by the method of Yamada et al.
( 1 9) with slight modification. Genomic DNA (1.5 pg) was mixed with 1 pM ofeach primer and 2 IU of Taq DNA polymerase (AmpliTaq; Perkin-Elmer Cetus, Norwalk, CT) in a final vol of 0.1 mL. Amplification was carried out for 37 cycles (94"C, I min; 5S°C, 1 min; and 72"C, 2 min).
The sequences of the amplified DNA fragments were determined directly by use of the sequencing primers (Table 2) . Only the synthesized DNA fragment corresponding to exon 1 of the UGT 1 D gene was subcloned into the pUC 19 vector (BoehringerMannheim, Mannheim, Germany) and sequenced. To exclude the effects of PCR errors, we determined the DNA sequences of nine clones.
DNA sequencing. Direct sequencing of DNA was performed by the method of Yamada et al. (19) . The pUC recombinants Table 1 . Oliaonucleotide urimers for am~lificatic were sequenced by the standard protocols provided with Sequenase 2.0 (United States Biochemical Co., Cleveland, OH). Nucleotide sequences were recorded on a personal computer and analyzed with GENETYX, version 8.0, gene analysis software (Software Development Co., Tokyo, Japan).
RESULTS

Identification of mutation in UGT genes.
We determined the DNA sequence of all the exons in the UGTlA and UGTID genes. DNA analysis of exons 2, 3,4, and 5 and of their flanking regions in the patient revealed no abnormal sequences, point mutations, or deletions as compared with the sequences for the normal controls (data not shown) and the published cDNA sequences (9) . However, direct determination of the DNA sequence of exon 1 of the UGTlA gene revealed that the patient was homozygous for a single nucleotide substitution of C by A at position 840 (9) in UGTlA cDNA (Fig. 1) . The observed point mutation (C -, A) changes the codon for cysteine at amino acid position 280 to a stop codon (TGA). We performed further analysis of the DNA sequence of exon 1 in the gene for the UGT1 D for our patient, but no other mutation was detected.
Familialgenetic analysis. The DNA sequence of exon 1 in the UGTlA gene was determined for each member of the patient's family. His parents (Fig. I ) and elder brother (not shown) were found to be heterozygous with respect to the mutation at base position 840.
DISCUSSION
From the clinical symptoms, such as severe unconjugated hyperbilirubinemia, trace levels of bilirubin glucuronides in the bile, and the absence of any effect on the total bilirubin level in the serum of the administration of phenobarbital, our patient was diagnosed as having CN type I.
We expected that a mutation would be detected in the common exons of the UGT I A and UGT 1 D genes, as found in other cases. Ritter et al. (14) , Bosma et al. (12) , and Moghrabi et al. (15) found a deletion of 13 nucleotides in exon 2 and a point mutation (at base position 1069 or 102 1 of the UGT 1 A cDNA) that resulted in a stop codon in exon 3, respectively, in their patients with CN type I. Bosma et al. (16) also reported two patients with a missense mutation in exon 4 and with a nonsense mutation in exon 2, respectively. Moreover, in the hyperbilirubinemic Gunn rat (20) , a model for CN type I (2 l), a -I frame shift mutation in the common 3' termini of cDNA for both bilirubin UGT (22) and phenol UGT (23) has been reported (24) (25) (26) . However, our patient with CN type I has a nonsense mutation in the unique exon I of the UGT1 A gene for bilirubin UGT protein, which is constitutively expressed (Fig. 1) . This is the first case of the identification of a mutation other than a mutation in the common exons (exons 2-5) of UGT genes in a case of CN type I.
It has been recognized that, among patients with CN type I, some show a reduction in UGT activity toward phenolic sub- strates, as expected, but some have normal enzymatic activity in this respect (27) . This observation indicates that some patients with CN type I have some defect in the exons I characteristic of each isoforms of UGT, in addition to patients with a mutation in the common exons. In this study, we confirmed this possibility by analyzing the DNA sequences of the UGT 1 A and UGT 1 D genes of a 1 -y-old male.
Predictably, the UGTlA protein of our patient lacks the carboxyl-terminal253 amino acids of the wild-type protein as a result of the point mutation and is completely, or almost completely, devoid of UGTlA enzymic activity. The origin of the trace amounts of conjugated bilirubin detected in bile and serum of the patient is presently unknown. Also puzzling is why the UGTlD gene, which was apparently normal, was unable to provide enough enzyme to catalyze formation of significant amounts of bilirubin conjugates, particularly after phenobarbital treatment.
On the other hand, Bosma et al. (28) described unexpected findings that patients with CN type I1 had a mutation not only in exon I of the UGTl A but also in exon I of the UGTl D, which is consistent with the report of Aono et al. (29) . On the basis of the study of the kindred, Bosma et al. (28) suggest that UGT I D do not significantly contribute to the physiologic disposition of bilirubin. Our result that only the defect in the exon I of the UGTlA gene is responsible for CN type I may be consistent with their notion.
